Romosozumab for Osteogenesis Imperfecta

"To be eligible for this medical trial, applicants must have Lobstein's Syndrome and should fall between the ages of 5 to 17. The researchers are looking to enrol 25 individuals in total."

"This study has an age requirement of 5-17years, so individuals that fit into this bracket are eligible to apply."

"The initial clinical trials for romosozumab were launched in 2020 at the Kessler Institute for Rehabilitation. To date, 217 such studies have been finished and 12 more are presently enrolling patients from Indianapolis, Indiana and its surrounding area."

"To date, 12 active research trials with Romosozumab are taking place in 13 cities of 9 nations. The initial investigation into the drug's efficacy began at Kessler Institute for Rehabilitation back in 2020 and involved 39 participants; it concluded its Phase 2 approval stage successfully. Moreover, a total of 217 studies have been finished since then."

"This trial is no longer open for recruitment, having been posted on January 21st 2021 and last updated October 25th 2022. If you are looking to participate in other studies, there are currently 10 trials involving Lobstein's Disease that require volunteers and 12 research initiatives recruiting participants who could benefit from Romosozumab treatments."

"Our evaluation at Power concluded that Romosozumab has a relatively low safety score of 1, as this is only in the early stages of clinical trials and there are limited data points on efficacy."

"The trial, which had its inception on the 21st of January 2021 and was last revised on October 25th 2022 is not currently enrolling. Nevertheless, there are 22 other clinical trials seeking participants."